General Toxicity Notes
May cause excessive sedation and encephalopathy in ESRD.
Excreted Unchanged %
Hepatic
Half-Life (Normalesrd) Hours
0.7-1.3/No data
Plasma Protein Binding %
40-50
Volume Of Distribution L/Kg
0.6-1.1
Dose For Normal Renal Function
0.2 mg IV over 15 sec
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs. 1991; 42: 1061-89. [PMID: 1724638] / Gaudreault P, Guay J, Thivierge RL, Verdy I. Benzodiazepine poisoning. Clinical and pharmacological considerations and treatment. Drug Saf. 1991; 6: 247-65. [PMID: 1888441] / Greenblatt DJ. Pharmacokinetics and pharmacodynamics. Hosp Pract (Off Ed). 1990; 25 Suppl 2: 9-15; discussion 16-8. [PMID: 2114417] / Greenblatt DJ. Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry. 1991; 52 Suppl: 4-10. [PMID: 1680125] / Karavokiros KA, Tsipis GB. Flumazenil: a benzodiazepine antagonist. DICP. 1990; 24: 976-81. [PMID: 2244412] / Treiman DM. Pharmacokinetics and clinical use of benzodiazepines in the management of status epilepticus. Epilepsia. 1989; 30 Suppl 2: S4-10. [PMID: 2670537] / Votey SR, Bosse GM, Bayer MJ, Hoffman JR. Flumazenil: a new benzodiazepine antagonist. Ann Emerg Med. 1991; 20: 181-8. [PMID: 1996802]
Toxicity Notes
Used in benzodiazepine overdose.